Paris, September 11, 2025 (Globe Newswire) – Bioptimus, a pioneering startup building the world's first universal foundation model of biology, today announced the formation of the Scientific Advisory Board (SAB), bringing together some of the most influential minds at the intersection of biology, artificial intelligence and medicine.
SAB guides Bioptimus's scientific strategy as the company pursues its ambitious mission. It is to develop large-scale AI models that can accelerate discovery across life sciences and change the way disease is understood and treated.
Board members represent an unparalleled network of global expertise spanning computational biology, genomics, oncology, systems biology, and AI.
- Dr. Sarah Teichmann, Chairman of SAB (Cambridge University) – World leader in single-cell genomics and co-founder of human cell Atlas.
- Jakob Nikolas Kather, MD, PhD (University Hospital Dresden) – Pioneering the application of AI to computational pathology and cancer diagnosis.
- Dr. Caroline Wooler (MIT, Broad Institute) – Famous experts in machine learning, causal reasoning, and genomics.
- Dr. Regina Bertilai (MIT, csail) – MacArthur Fellow in AI-led drug discovery and precision medicine and key authority.
- Nikolaus Rajewsky, PhD (BIMSB, MDC Berlin) – Pioneer in health systems biology and a global leader in RNA research and spatial omics.
- Dr. Fabrice Andre (GustaveRoussy) – Internationally recognized cancer researcher and translational oncology expert.
- Dr. John Connolly (Parker Institute for Cancer Immunotherapy, National University of Singapore) – An immunology innovator driving next-generation cell-based therapies.
- Andrea California, Ph.D. (Columbia University, CZ Biohub NYC) – Systems Biology Pioneer and AI-driven drug discovery pioneer.
“To solve the deepest biology challenges, we need to build models at scale and fidelity that have never been attempted before,” said Jean-Philippe Vert, CEO and co-founder of Bioptimus. “This SAB connects the extraordinary constellations of global leaders across expertise across biology, AI and medicine. Their guidance will contribute to pursuing our mission to change the future of life sciences.”
The basic model of Bioptimus is designed to integrate multiscale biological data ranging from molecular profiles to all-gas systems.
“Bioptimus has the potential to fundamentally reshape biological research and medicine,” said Sarah Teichmann, chairman of the SAB. “We are excited to join this exceptional team and help shape the future of AI-driven biology.”
With this announcement, Bioptimus demonstrates scientific ambitions and global leadership, bringing together experts from major institutions in Europe, the US and the world.
About Bioptimus
Bioptimus is a global AI high-tech company pioneering the world's first universal foundation model biological model. By combining cutting-edge AI with large-scale multimodal and unique data generation, Bioptimus brings together every scale of biology, from the molecular to patient, a framework that provides interpretable, dynamic, practical insights. The first model released by Bioptimus, H-Optimus is an industry-leading model adopted throughout the research, drug discovery and clinical pipeline.
Photos accompanying this announcement are available at: https://www.globenewswire.com/newsroom/attachmentng/898eaffe-4d5d-4e49-82a6-566c9fafd516
